AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy
Nucleic Acids Research · 20.03.2025 · 53 (6)
DOI: 10.1093/nar/gkaf241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 04.04.2025. Verfasst von Usue Etxaniz und 24 weiteren Autor:innen. Beteiligte Einrichtung: Avidity Biosciences, Inc., 10578 Science Drive, Suite 125, San Diego, CA 92121, United States. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Dystrophin, Exons, Morpholinos. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Avidity Biosciences, Inc.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is a severe disorder caused by mutations in the dystrophin gene, resulting in loss of functional dystrophin protein in muscle. While phosphorodiamidate morpholino oligomers (PMOs) are promising exon-skipping therapeutics aimed at restoring dystrophin expression, their effectiveness is often limited by poor muscle delivery. We developed AOC 1044, an antibody–oligonucleotide conjugate (AOC) that combines a PMO-targeting exon 44 with an antibody against the transferrin receptor (TfR1), enhancing delivery to muscle tissues for patients with DMD amenable to exon 44 skipping (DMD44). AOC 1044 induces dose-dependent exon 44 skipping and its mouse-active variant elicited dose-dependent dystrophin restoration in skeletal and cardiac muscle in a DMD mouse model. This treatment also reduced muscle damage, as evidenced by decreases in serum creatine kinase and key liver enzymes, suggesting that restored dystrophin is functionally active. In nonhuman primates, single or repeated AOC 1044 doses resulted in dose-dependent increases in PMO concentration and exon 44 skipping across a range of muscle tissues, including the heart. Collectively, these findings highlight AOC 1044 as a promising therapeutic candidate for patients with DMD44, offering improved muscle targeting and meaningful dystrophin restoration, with potential clinical benefits in reducing muscle degeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Avidity Biosciences, Inc., 10578 Science Drive, Suite 125, San Diego, CA 92121, United States.
- Seawolf Therapeutics, 9880 Campus Point Drive, Suite 210, San Diego, CA 92121, United States.
- Broad Institute of MIT and Harvard, 75 Ames Street, Cambridge, MA 02142, United States.
- Yokota Lab, Department of Medical Genetics, University of Alberta, Edmonton,T6G 2H, Canada.
ORCID-Profile: Usue Etxaniz
Förderung
- Avidity Biosciences, Inc
Zitieren
APA
Etxaniz, U., Marks, I., Albin, T., Diaz, M., Bhardwaj, R., Anderson, A., Tyaglo, O., Hoang, T., Missinato, M. A., Svensson, K., Badillo, B., Kovach, P. R., Leung, L., Cochran, M., Kwon, H. W., Ahad Shah, M. N., Maruyama, R., Yokota, T., Doppalapudi, V. R., …, & Karamanlidis, G. (2025). AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy. Nucleic Acids Research, 53(6). https://doi.org/10.1093/nar/gkaf241
Vancouver
Etxaniz U, Marks I, Albin T, Diaz M, Bhardwaj R, Anderson A, et al. AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy. Nucleic Acids Research. 2025;53(6). doi:10.1093/nar/gkaf241
BibTeX
@article{Etxaniz2025,
author = {Etxaniz, Usue and Marks, Isaac and Albin, Tyler and Diaz, Matthew and Bhardwaj, Raghav and Anderson, Aaron and Tyaglo, Olecya and Hoang, Tiffany and Missinato, Maria Azzurra and Svensson, Kristoffer and Badillo, Ben and Kovach, Philip R and Leung, Laura and Cochran, Michael and Kwon, Hae Won and Ahad Shah, Md Nur and Maruyama, Rika and Yokota, Toshifumi and Doppalapudi, Venkata R and Darimont, Beatrice and Younis, Husam S and Flanagan, W Michael and Levin, Arthur A and Huang, Hanhua and Karamanlidis, Georgios},
title = {AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {6},
doi = {10.1093/nar/gkaf241}
}
EUVIMED